{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:59:14Z","timestamp":1790834354230,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","award":["grant R764"],"award-info":[{"award-number":["grant R764"]}],"id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-026-12792-1","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T12:35:23Z","timestamp":1786624523000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Total diffusion volume on whole-body diffusion-weighted imaging is a strong prognostic marker of disease survival in metastatic castration-resistant prostate cancer"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7443-3739","authenticated-orcid":false,"given":"Luca","family":"D\u2019Erme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Avesani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bottazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Whitcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Candito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robby","family":"Emsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Meo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Paschalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Tunariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dow-Mu","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"12792_CR1","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1038\/onc.2013.206","volume":"32","author":"T Karantanos","year":"2013","unstructured":"Karantanos T, Corn PG, Thompson TC (2013) Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32:5501\u20135511. https:\/\/doi.org\/10.1038\/onc.2013.206","journal-title":"Oncogene"},{"key":"12792_CR2","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.3349\/ymj.2015.56.5.1206","volume":"56","author":"KC Koo","year":"2015","unstructured":"Koo KC, Park SU, Kim KH et al (2015) Prognostic impacts of metastatic site and pain on progression to castrate resistance and mortality in patients with metastatic prostate cancer. Yonsei Med J 56:1206. https:\/\/doi.org\/10.3349\/ymj.2015.56.5.1206","journal-title":"Yonsei Med J"},{"key":"12792_CR3","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-473636","volume":"45","author":"W Abida","year":"2025","unstructured":"Abida W, Beltran H, Raychaudhuri R (2025) State of the art: personalizing treatment for patients with metastatic castration-resistant prostate cancer. Am Soc Clin Oncol Educ Book 45:e473636. https:\/\/doi.org\/10.1200\/EDBK-25-473636","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"12792_CR4","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1200\/JCO.20.01035","volume":"38","author":"W Abida","year":"2020","unstructured":"Abida W, Patnaik A, Campbell D et al (2020) Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol 38:3763\u20133772. https:\/\/doi.org\/10.1200\/JCO.20.01035","journal-title":"J Clin Oncol"},{"key":"12792_CR5","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J De Bono","year":"2020","unstructured":"De Bono J, Mateo J, Fizazi K et al (2020) Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382:2091\u20132102. https:\/\/doi.org\/10.1056\/NEJMoa1911440","journal-title":"N Engl J Med"},{"key":"12792_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Piulats JM, Gross-Goupil M et al (2020) Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol 38:395\u2013405. https:\/\/doi.org\/10.1200\/JCO.19.01638","journal-title":"J Clin Oncol"},{"key":"12792_CR7","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s11864-024-01215-2","volume":"25","author":"T Kulasegaran","year":"2024","unstructured":"Kulasegaran T, Oliveira N (2024) Metastatic castration-resistant prostate cancer: advances in treatment and symptom management. Curr Treat Options Oncol 25:914\u2013931. https:\/\/doi.org\/10.1007\/s11864-024-01215-2","journal-title":"Curr Treat Options Oncol"},{"key":"12792_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2174\/1568009615666150204145803","volume":"15","author":"M Boegemann","year":"2015","unstructured":"Boegemann M, Schrader A-J, Krabbe L-M, Herrmann E (2015) Present, emerging and possible future biomarkers in castration resistant prostate cancer (CRPC). Curr Cancer Drug Targets 15:243\u2013255. https:\/\/doi.org\/10.2174\/1568009615666150204145803","journal-title":"Curr Cancer Drug Targets"},{"key":"12792_CR9","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K et al (2020) Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:1119\u20131134. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.011","journal-title":"Ann Oncol"},{"key":"12792_CR10","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM et al (2016) Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 34:1402\u20131418. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702","journal-title":"J Clin Oncol"},{"key":"12792_CR11","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1200\/JCO.1999.17.3.948","volume":"17","author":"P Sabbatini","year":"1999","unstructured":"Sabbatini P, Larson SM, Kremer A et al (1999) Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 17:948\u2013948. https:\/\/doi.org\/10.1200\/JCO.1999.17.3.948","journal-title":"J Clin Oncol"},{"key":"12792_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-016-0173-z","volume":"6","author":"A Anand","year":"2016","unstructured":"Anand A, Morris MJ, Larson SM et al (2016) Automated bone scan index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide. EJNMMI Res 6:23. https:\/\/doi.org\/10.1186\/s13550-016-0173-z","journal-title":"EJNMMI Res"},{"key":"12792_CR13","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamaoncol.2018.1093","volume":"4","author":"AJ Armstrong","year":"2018","unstructured":"Armstrong AJ, Anand A, Edenbrandt L et al (2018) Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol 4:944. https:\/\/doi.org\/10.1001\/jamaoncol.2018.1093","journal-title":"JAMA Oncol"},{"key":"12792_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4401-y","volume":"18","author":"K Uemura","year":"2018","unstructured":"Uemura K, Miyoshi Y, Kawahara T et al (2018) Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel. BMC Cancer 18:501. https:\/\/doi.org\/10.1186\/s12885-018-4401-y","journal-title":"BMC Cancer"},{"key":"12792_CR15","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.3390\/cancers16142531","volume":"16","author":"A Cattabriga","year":"2024","unstructured":"Cattabriga A, Renzetti B, Galuppi F et al (2024) Multiparametric whole-body MRI: a game changer in metastatic prostate cancer. Cancers 16:2531. https:\/\/doi.org\/10.3390\/cancers16142531","journal-title":"Cancers"},{"key":"12792_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.eururo.2012.02.020","volume":"62","author":"FE Lecouvet","year":"2012","unstructured":"Lecouvet FE, El Mouedden J, Collette L et al (2012) Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62:68\u201375. https:\/\/doi.org\/10.1016\/j.eururo.2012.02.020","journal-title":"Eur Urol"},{"key":"12792_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1148\/radiol.2015150799","volume":"280","author":"R Perez-Lopez","year":"2016","unstructured":"Perez-Lopez R, Lorente D, Blackledge MD et al (2016) Volume of bone metastasis assessed with whole-body diffusion-weighted imaging is associated with overall survival in metastatic castration-resistant prostate cancer. Radiology 280:151\u2013160. https:\/\/doi.org\/10.1148\/radiol.2015150799","journal-title":"Radiology"},{"key":"12792_CR18","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1148\/radiol.2016160646","volume":"283","author":"R Perez-Lopez","year":"2017","unstructured":"Perez-Lopez R, Mateo J, Mossop H et al (2017) Diffusion-weighted imaging as a treatment response biomarker for evaluating bone metastases in prostate cancer: a pilot study. Radiology 283:168\u2013177. https:\/\/doi.org\/10.1148\/radiol.2016160646","journal-title":"Radiology"},{"key":"12792_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.mric.2018.06.002","volume":"26","author":"R Donners","year":"2018","unstructured":"Donners R, Blackledge M, Tunariu N et al (2018) Quantitative whole-body diffusion-weighted MR imaging. Magn Reson Imaging Clin N Am 26:479\u2013494. https:\/\/doi.org\/10.1016\/j.mric.2018.06.002","journal-title":"Magn Reson Imaging Clin N Am"},{"key":"12792_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/jmri.27596","volume":"54","author":"S Yamamoto","year":"2021","unstructured":"Yamamoto S, Yoshida S, Ishii C et al (2021) Metastatic diffusion volume based on apparent diffusion coefficient as a prognostic factor in Castration-Resistant prostate cancer. J Magn Reson Imaging 54:401\u2013408. https:\/\/doi.org\/10.1002\/jmri.27596","journal-title":"J Magn Reson Imaging"},{"key":"12792_CR21","doi-asserted-by":"publisher","first-page":"e91779","DOI":"10.1371\/journal.pone.0091779","volume":"9","author":"MD Blackledge","year":"2014","unstructured":"Blackledge MD, Collins DJ, Tunariu N et al (2014) Assessment of treatment response by total tumor volume and global apparent diffusion coefficient using diffusion-weighted MRI in patients with metastatic bone disease: a feasibility study. PLoS One 9:e91779. https:\/\/doi.org\/10.1371\/journal.pone.0091779","journal-title":"PLoS One"},{"key":"12792_CR22","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.euf.2016.12.006","volume":"2","author":"RJ Van Soest","year":"2016","unstructured":"Van Soest RJ, Efstathiou JA, Sternberg CN, Tombal B (2016) The natural history and outcome predictors of metastatic castration-resistant prostate cancer. Eur Urol Focus 2:480\u2013487. https:\/\/doi.org\/10.1016\/j.euf.2016.12.006","journal-title":"Eur Urol Focus"},{"key":"12792_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/JCO.2013.52.3696","volume":"32","author":"S Halabi","year":"2014","unstructured":"Halabi S, Lin C-Y, Kelly WK et al (2014) Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol 32:671\u2013677. https:\/\/doi.org\/10.1200\/JCO.2013.52.3696","journal-title":"J Clin Oncol"},{"key":"12792_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10700-0","volume":"23","author":"T Kawahara","year":"2023","unstructured":"Kawahara T, Saigusa Y, Yoneyama S et al (2023) Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and\/or enzalutamide. BMC Cancer 23:214. https:\/\/doi.org\/10.1186\/s12885-023-10700-0","journal-title":"BMC Cancer"},{"key":"12792_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2016.05.033","volume":"71","author":"AR Padhani","year":"2017","unstructured":"Padhani AR, Lecouvet FE, Tunariu N et al (2017) METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 71:81\u201392. https:\/\/doi.org\/10.1016\/j.eururo.2016.05.033","journal-title":"Eur Urol"},{"key":"12792_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bspc.2024.106099","volume":"92","author":"A Candito","year":"2024","unstructured":"Candito A, Holbrey R, Ribeiro A et al (2024) Deep learning assisted atlas-based delineation of the skeleton from whole-body diffusion weighted MRI in patients with malignant bone disease. Biomed Signal Process Control 92:106099. https:\/\/doi.org\/10.1016\/j.bspc.2024.106099","journal-title":"Biomed Signal Process Control"},{"key":"12792_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2025.109043","volume":"272","author":"A Candito","year":"2025","unstructured":"Candito A, Dragan A, Holbrey R et al (2025) A weakly-supervised deep learning model for fast localisation and delineation of the skeleton, internal organs, and spinal canal on whole-body diffusion-weighted MRI (WB-DWI). Comput Methods Programs Biomed 272:109043. https:\/\/doi.org\/10.1016\/j.cmpb.2025.109043","journal-title":"Comput Methods Programs Biomed"},{"key":"12792_CR28","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3390\/bioengineering11020130","volume":"11","author":"A Candito","year":"2024","unstructured":"Candito A, Holbrey R, Ribeiro A et al (2024) Deep learning for delineation of the spinal canal in whole-body diffusion-weighted imaging: normalising inter- and intra-patient intensity signal in multi-centre datasets. Bioengineering 11:130. https:\/\/doi.org\/10.3390\/bioengineering11020130","journal-title":"Bioengineering"},{"key":"12792_CR29","doi-asserted-by":"publisher","first-page":"225021","DOI":"10.1088\/1361-6560\/ae19c5","volume":"70","author":"A Candito","year":"2025","unstructured":"Candito A, Blackledge MD, Holbrey R et al (2025) AI-driven software for automated quantification of skeletal metastases and treatment response evaluation using whole-body diffusion-weighted MRI (WB-DWI) in advanced prostate cancer. Phys Med Biol 70:225021. https:\/\/doi.org\/10.1088\/1361-6560\/ae19c5","journal-title":"Phys Med Biol"}],"updated-by":[{"DOI":"10.1007\/s00330-026-12928-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000}}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-026-12792-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-026-12792-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-026-12792-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:27:06Z","timestamp":1790832426000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-026-12792-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":29,"alternative-id":["12792"],"URL":"https:\/\/doi.org\/10.1007\/s00330-026-12792-1","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In this article the author\u2019s name Dow-Mu Koh was incorrectly written as Doh-Mu Koh. In the Acknowledgements section of this article the grant number relating to Prostate Cancer UK was incorrectly given as R746 and should have been RIA-18-ST2-023.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00330-026-12928-3","URL":"https:\/\/doi.org\/10.1007\/s00330-026-12928-3","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The scientific guarantor of this publication is Prof. Dow-Mu Koh.","order":1,"name":"Ethics","label":"Guarantor","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No complex statistical methods were necessary for this paper.","order":3,"name":"Ethics","label":"Statistics and biometry","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":4,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Institutional Review Board approval was obtained.","order":5,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":6,"name":"Ethics","label":"Study subjects or cohorts overlap","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"order":7,"name":"Ethics","label":"Methodology","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}